TKT and cancer: The anti-EGFRvIII ribozyme approach seems to cause rather a cytostatic than a cytocidal effect as opposed to the HSV-TK/GCV strategy, and a therapeutic benefit may be rather derived from increased susceptibility of targeted cancer cells towards conventional and new therapeutic modalities and agents.